aTyr PharmaATYR -5.75%14 PB Ratio is 0.94 as of Jun. 26, 2026, which is 17% below its 10-year median of 1.13. GuruFocus rates ATYR with a GF Score™ of 14/100 and a GF Value™ of $0.46 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,232 Biotechnology companies, aTyr Pharma ranks better than 83.52% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), aTyr Pharma's share price is $0.5554. aTyr Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was $0.59. Hence, aTyr Pharma's PB Ratio of today is 0.94.
The historical rank and industry rank for aTyr Pharma's PB Ratio or its related term are showing as below:
ATYR'
s PB Ratio Range Over the Past 10 Years
Min: 0.34 Med: 1.13 Max: 7.24
Current: 0.89
During the past 13 years, aTyr Pharma's highest PB Ratio was 7.24. The lowest was 0.34. And the median was 1.13.
ATYR's PB Ratio is ranked better than 83.52% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs ATYR: 0.89
During the past 12 months, aTyr Pharma's average Book Value Per Share Growth Rate was -29.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -34.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -29.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -37.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of aTyr Pharma was -20.70% per year. The lowest was -54.30% per year. And the median was -37.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
aTyr Pharma PB Ratio Related Terms
aTyr Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for aTyr Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, aTyr Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
aTyr Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, aTyr Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where aTyr Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
aTyr Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
aTyr Pharma (ATYR) has a PB Ratio of 0.94 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on aTyr Pharma and its competitors. This is 17% below median its historical median of 1.13. Over the past decade, aTyr Pharma's PB Ratio has ranged from 0.34 to 7.24. According to the industry distribution chart, aTyr Pharma ranks #203 out of 1232 companies in the Biotechnology industry, placing it in the top 16.5%.
Is aTyr Pharma's PB Ratio too high?
aTyr Pharma's current PB Ratio of 0.94 is 17% below median its 10-year median of 1.13. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 7.24. The Biotechnology industry median PB Ratio is 2.80. aTyr Pharma's value of 0.94 is 66.4% below this industry median. Based on the distribution chart, aTyr Pharma ranks #203 out of 1232 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, aTyr Pharma has a GF Score™ of 14/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's PB Ratio compare to HYPD and GOSS?
According to the Biotechnology industry distribution chart, aTyr Pharma ranks #203 out of 1232 companies for PB Ratio. This places aTyr Pharma in the top 17% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. aTyr Pharma's value of 0.94 is 66.4% below this benchmark. Historically, aTyr Pharma's own PB Ratio has ranged from 0.34 to 7.24 over the past decade. While the company's 10-year median is 1.13 vs. the industry median of 2.80, aTyr Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. aTyr Pharma's current PB Ratio of 0.94 is 66.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on aTyr Pharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. aTyr Pharma's current PB Ratio is 0.94, which is 17% below median its own 10-year median of 1.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (ATYR) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.46, compared to a current price of $0.56 — trading 20.7% above its estimated fair value. The current PB Ratio is 0.94, which is 17% below median its 10-year median of 1.13 and 66.4% below the Biotechnology industry median of 2.80. aTyr Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For aTyr Pharma (ATYR), the current PB Ratio is 0.94 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is aTyr Pharma (ATYR) Overvalued in 2026?
Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued.
The current stock price of $0.56 is trading 20.7% above its estimated GF Value™ of $0.46.
GuruFocus considers aTyr Pharma to be Modestly Overvalued.
Key valuation signals for ATYR:
PB Ratio: 0.94 (17% below median its 10-year median of 1.13)
GF Value™: $0.46 vs. price of $0.56 (20.7% above fair value)
Industry Position: 66.4% below the Biotechnology median (#203 of 1232)
No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
14GF Score
Get the complete analysis for ATYR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATYR has been successfully added to your 
